Oruka Therapeutics (ORKA) Total Liabilities (2010 - 2026)
Oruka Therapeutics' quarterly Total Liabilities came in at $17.8 million in Q1 2026, up 43.38% year-on-year from $12.4 million in Q1 2025, and up 6.43% quarter-over-quarter from $16.7 million in Q4 2025.
Oruka Therapeutics has reported Total Liabilities for 17 years, with the latest figure at $17.8 million in Q1 2026.
- For the quarter ending Q1 2026, Total Liabilities rose 43.38% year-over-year to $17.8 million; the trailing twelve-month figure through Mar 2026 stood at $17.8 million (up 43.38% YoY), and the FY2025 full-year result was $16.7 million, up 20.94% from the prior year.
- Total Liabilities for Q1 2026 stood at $17.8 million, up from $16.7 million in the prior quarter.
- The five-year high for Total Liabilities was $22.5 million in Q3 2025, with the low at $841000.0 in Q4 2023.
- Average Total Liabilities over 5 years is $7.9 million, with a median of $3.1 million recorded in 2022.
- Year-over-year, Total Liabilities plunged 63.62% in 2022 and soared 1540.67% in 2024.
- Tracing ORKA's Total Liabilities over 5 years: stood at $1.4 million in 2022, then tumbled by 40.44% to $841000.0 in 2023, then soared by 1540.67% to $13.8 million in 2024, then rose by 20.94% to $16.7 million in 2025, then climbed by 6.43% to $17.8 million in 2026.
- The last three Total Liabilities figures came in at $17.8 million (Q1 2026), $16.7 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 16.35 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 1.74 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 731.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 177.22 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 19.51 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.12 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 10.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 9.45 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Oruka Therapeutics | 3.04 Bn | 2.65 Bn | - | 17.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.76 Mn |
| Dec 31, 2025 | 16.69 Mn |
| Sep 30, 2025 | 22.46 Mn |
| Jun 30, 2025 | 13.78 Mn |
| Mar 31, 2025 | 12.39 Mn |
| Dec 31, 2024 | 13.80 Mn |
| Sep 30, 2024 | 18.88 Mn |
| Jun 30, 2024 | 1.27 Mn |
| Mar 31, 2024 | 1.58 Mn |
| Dec 31, 2023 | 841,000.00 |
| Sep 30, 2023 | 1.22 Mn |
| Jun 30, 2023 | 1.85 Mn |
| Mar 31, 2023 | 1.53 Mn |
| Dec 31, 2022 | 1.41 Mn |
| Sep 30, 2022 | 2.24 Mn |
| Jun 30, 2022 | 3.14 Mn |
| Mar 31, 2022 | 3.08 Mn |
| Dec 31, 2021 | 3.88 Mn |
| Sep 30, 2021 | 3.59 Mn |
| Jun 30, 2021 | 4.13 Mn |
| Mar 31, 2021 | 3.27 Mn |
| Dec 31, 2020 | 3.91 Mn |
| Sep 30, 2020 | 1.53 Mn |
| Jun 30, 2020 | 1.33 Mn |
| Mar 31, 2020 | 1.16 Mn |
| Dec 31, 2019 | 926,000.00 |
| Sep 30, 2019 | 1.15 Mn |
| Jun 30, 2019 | 1.20 Mn |
| Mar 31, 2019 | 1.29 Mn |
| Dec 31, 2018 | 793,000.00 |
| Sep 30, 2018 | 982,000.00 |
| Jun 30, 2018 | 1.07 Mn |
| Mar 31, 2018 | 1.73 Mn |
| Dec 31, 2017 | 2.09 Mn |
| Sep 30, 2017 | 2.57 Mn |
| Jun 30, 2017 | 2.55 Mn |
| Mar 31, 2017 | 2.55 Mn |
| Dec 31, 2016 | 2.44 Mn |
| Sep 30, 2016 | 2.20 Mn |
| Jun 30, 2016 | 1.74 Mn |
| Mar 31, 2016 | 2.34 Mn |
| Dec 31, 2015 | 1.50 Mn |
| Sep 30, 2015 | 1.30 Mn |
| Jun 30, 2015 | 1.36 Mn |
| Mar 31, 2015 | 1.13 Mn |
| Dec 31, 2014 | 1.39 Mn |
| Sep 30, 2014 | 841,000.00 |
| Jun 30, 2014 | 1.22 Mn |
| Mar 31, 2014 | 1.12 Mn |
| Dec 31, 2013 | 1.50 Mn |
| Sep 30, 2013 | 769,000.00 |
| Jun 30, 2013 | 750,000.00 |
| Mar 31, 2013 | 828,000.00 |
| Dec 31, 2012 | 305,000.00 |
| Sep 30, 2012 | 286,000.00 |
| Jun 30, 2012 | 529,000.00 |
| Mar 31, 2012 | 602,000.00 |
| Dec 31, 2011 | 770,000.00 |
| Sep 30, 2011 | 686,000.00 |
| Jun 30, 2011 | 1.04 Mn |
| Dec 31, 2010 | 1.39 Mn |